Medical financial hardship among cancer survivors in the United States: What do we know? What do we need to know?

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 12, 2018, Pages 1389-1397

  Yabroff, K Robin ^a   Zhao, Jingxuan ^a   Zheng, Zhiyuan ^a   Rai, Ashish ^a   Han, Xuesong ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER SURVIVAL; CANCER SURVIVOR; CONCEPTUAL FRAMEWORK; EMPLOYER; HEALTH CARE SYSTEM; HUMAN; REVIEW; RISK FACTOR; UNITED STATES; COST OF ILLNESS; PSYCHOLOGY; QUESTIONNAIRE;

CANCER SURVIVORS; COST OF ILLNESS; HUMANS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 85057750232     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-18-0617     Document Type: Review

References (97)

1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117–28.
2. Conti RM, Fein AJ, Bhatta SS. National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011. Health Aff 2014;33:1721–7.
3. Shih YT, Xu Y, Liu L, Smieliauskas F. Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries. J Clin Oncol 2017;35:2482–9.
4. Lee JA, Roehrig CS, Butto ED. Cancer care cost trends in the United States: 1998 to 2012. Cancer 2016;122:1078–84.
5. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626–33.
6. Memorial Sloan Kettering Cancer Center. Price and value of cancer drug. Available from: https://www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs.
7. Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic treatment of advanced-stage non-small-cell lung cancer: treatment, survival, and spending (2000 to 2011). J Clin Oncol 2017;35: 529–35.
8. Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB. Trends in the treatment of metastatic colon and rectal cancer in elderly patients. Med Care 2016;54:490–7.
9. Zheng Z, Yabroff KR, Guy GP Jr., Han X, Li C, Banegas MP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst 2016;108.
10. Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013;119:1257–65.
11. Guy GP Jr., Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 2013;31:3749–57.
12. Shankaran V, Ramsey S. Addressing the financial burden of cancer treatment: from copay to can't pay. JAMA Oncol 2015;1:273–4.
13. Henry J. Kaiser Family Foundation. Payments for cost sharing increasing rapidly over time 2017. Available from: https://www.kff.org/health-costs/issue-brief/payments-for-cost-sharing-increasing-rapidly-over-time/.
14. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 2017;109.
15. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018;68:153–65.
16. Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 2017;10:295–309.
17. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013;18:381–90.
18. Rim SH, Guy GP Jr., Yabroff KR, McGraw KA, Ekwueme DU. The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review. Exp Rev Pharmacoecon Outcomes Res 2016;16: 579–89.
19. Wheeler SB, Spencer JC, Pinheiro LC, Carey LA, Olshan AF, Reeder-Hayes KE. Financial impact of breast cancer in black versus white women. J Clin Oncol 2018:Jco2017776310.
20. Nipp RD, Kirchhoff AC, Fair D, Rabin J, Hyland KA, Kuhlthau K, et al. Financial burden in survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2017;35:3474–81.
21. Nipp RD, Zullig LL, Samsa G, Peppercorn JM, Schrag D, Taylor DH Jr, et al. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. Psychooncology 2016;25:719–25.
22. Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer 2010;116:3493–504.
23. Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 2013;119:3710–7.
24. Pisu M, Kenzik KM, Oster RA, Drentea P, Ashing KT, Fouad M, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer 2015;121: 1257–64.
25. Jagsi R, Pottow JA, Griffith KA, Bradley C, Hamilton AS, Graff J, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32:1269–76.
26. Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE. Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol Biomarkers Prev 2013;22:1668–76.
27. Banegas MP, Guy GP Jr., de Moor JS, Ekwueme DU, Virgo KS, Kent EE, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff 2016;35:54–61.
28. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 2004;96:1322–30.
29. Mehnert A, de Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer 2013;119:2151–9.
30. Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff 2013;32:1143–52.
31. Weaver KE, Rowland JH, Alfano CM, McNeel TS. Parental cancer and the family: a population-based estimate of the number of US cancer survivors residing with their minor children. Cancer 2010;116:4395–401.
32. Levitt L. Why health insurance literacy matters. JAMA 2015;313:555–6.
33. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016;34:980–6.
34. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, Chubak J. Cancer survivors' experiences with insurance, finances, and employment: results from a multisite study. J Cancer Surviv 2016;10:1104–11.
35. Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15:883–93.
36. Nathan PC HT, Kirchhoff AC, Park ER, Yabroff KR. Financial hardship and the economic impact of childhood cancer survivorship.J Clin Oncol 2018. In press.
37. Yabroff KR, Saraiya M, Meissner HI, Haggstrom DA, Wideroff L, Yuan G, et al. Specialty differences in primary care physician reports of papanico-laou test screening practices: a national survey, 2006 to 2007. Ann Intern Med 2009;151:602–11.
38. Tsugawa Y, Newhouse JP, Zaslavsky AM, Blumenthal DM, Jena AB. Physician age and outcomes in elderly patients in hospital in the US: observational study. BMJ 2017;357:j1797.
39. Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 2009;115: 3848–57.
40. Wright JD, Neugut AI, Wilde ET, Buono DL, Malin J, Tsai WY, et al. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 2011;29:3408–18.
41. Wilson LE, Pollack CE, Greiner MA, Dinan MA. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011. Breast Cancer Res Treat 2018;170:361–71.
42. Kimmick GG, Camacho F, Mackley HB, Kern T, Yao N, Matthews SA, et al. Individual, area, and provider characteristics associated with care received for stages I to III breast cancer in a multistate region of appalachia. J Oncol Pract 2015;11:e9–e18.
43. Yabroff KR, Zapka J, Klabunde CN, Yuan G, Buckman DW, Haggstrom D, et al. Systems strategies to support cancer screening in U.S. primary care practice. Cancer Epidemiol Biomarkers Prev 2011;20:2471–9.
44. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, et al. American society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868–74.
45. Institute of Medicine. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington, DC: The National Academies Press; 2013.
46. Shih YT, Chien CR. A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment. Cancer 2017;123:928–39.
47. Wollins DS, Zafar SY. A touchy subject: can physicians improve value by discussing costs and clinical benefits with patients? Oncologist 2016;21: 1157–60.
48. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health 2003;93: 635–41.
49. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487–97.
50. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088–97.
51. Park Y, Raza S, George A, Agrawal R, Ko J. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Special Pharm 2017;23:893–901.
52. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32:306–11.
53. Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol 2016;34:4323–8.
54. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120–8.
55. de Moor JS, Dowling EC, Ekwueme DU, Guy GP Jr, Rodriguez J, Virgo KS, et al. Employment implications of informal cancer caregiving. J Cancer Surviv 2017;11:48–57.
56. US Department of Labor. Fact sheet #28: the family and medical leave act. Available from: https://www.dol.gov/whd/regs/compliance/whdfs28.pdf.
57. National Conference of State Legislatures. State Family and Medical Leave Laws. Available from: http://www.ncsl.org/research/labor-andemployment/state-family-and-medical-leave-laws.aspx.
58. Han X, Yabroff KR, Robbins AS, Zheng Z, Jemal A. Dependent coverage and use of preventive care under the Affordable Care Act. N Engl J Med 2014;371:2341–2.
59. Robbins AS, Han X, Ward EM, Simard EP, Zheng Z, Jemal A. Association between the affordable care act dependent coverage expansion and cervical cancer stage and treatment in young women. JAMA 2015;314:2189–91.
60. Wallace J, Sommers BD. Effect of dependent coverage expansion of the Affordable Care Act on health and access to care for young adults. JAMA Pediatr 2015;169:495–7.
61. Han X, Zang Xiong K, Kramer MR, Jemal A. The affordable care act and cancer stage at diagnosis among young adults. J Natl Cancer Inst 2016;108.
62. Jemal A, Lin CC, Davidoff AJ, Han X. Changes in insurance coverage and stage at diagnosis among nonelderly patients with cancer after the affordable care act. J Clin Oncol 2017;35:3906–15.
63. Davidoff AJ, Guy GP Jr, Hu X, Gonzales F, Han X, Zheng Z, et al. Changes in health insurance coverage associated with the affordable care act among adults with and without a cancer history: population-based national estimates. Med Care 2018;56:220–7.
64. Soni A, Simon K, Cawley J, Sabik L. Effect of medicaid expansions of 2014 on overall and early-stage cancer diagnoses. Am J Public Health 2018;108: 216–8.
65. Soni A, Sabik LM, Simon K, Sommers BD. Changes in insurance coverage among cancer patients under the affordable care act. JAMA Oncol 2018;4: 122–4.
66. Brooks T, Wagnerman K, Artiga S, Cornachione E. Medicaid and CHIP eligibility, enrollment, renewal, and cost sharing policies as of January 2018: findings from a 50-state survey. Available from: https://www.kff.org/medicaid/report/medicaid-and-chip-eligibility-enrollment-renewal-and-costsharing-policies-as-of-january-2018-findings-from-a-50-state-survey/.
67. Henry J. Kaiser Family Foundation. Medicaid benefits: physician services. Available from: https://www.kff.org/medicaid/state-indicator/physicianservices/?currentTimeframe=0&sortModel=%7B%22colId%22:%22 Location%22,%22sort%22:%22asc%22%7D.
68. Henry J Kaiser Family Foundation. Medicaid benefits: prescription drugs.
69. Henry J Kaiser Family Foundation. What are states proposing for work requirements in Medicaid? 2018.
70. National Academy for State Health Policy. State legislative action on pharmaceutical prices. 2018. Available from: https://nashp.org/statelegislative-action-on-pharmaceutical-prices/.
71. Sarpatwari A, Avorn J, Kesselheim AS. State initiatives to control medication costs–can transparency legislation help? N Engl J Med 2016;374: 2301–4.
72. Printz C. Drug parity legislation: states, organizations seek to make oral cancer drugs more affordable. Cancer 2014;120:313–4.
73. Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL. Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws. JAMA Oncol 2018;4: e173598.
74. Prawitz AD, Garman ET, Sorhaindo B, O'Neill B, Kim J, Drentea P. The incharge financial distress/financial well-being scale: establishing validity and reliability. Fin Counsel Plan 2006;17:34–50.
75. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, et al. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 2014;120:3245–53.
76. de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017;123:476–84.
77. National Center for Health Statistics. National health interview survey. Available from: https://www.cdc.gov/nchs/nhis/index.htm.
78. Agency for Healthcare Research and Quality. Medical expenditure panel survey. Available from: https://meps.ahrq.gov/mepsweb/.
79. Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. Available from: https://www.cdc.gov/brfss/index.html.
80. Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer 2017;123:1453–63.
81. Yabroff KR, Dowling E, Rodriguez J, Ekwueme DU, Meissner H, Soni A, et al. The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv 2012;6:407–19.
82. Ross JS, Kesselheim AS. Prescription-drug coupons–no such thing as a free lunch. N Engl J Med 2013;369:1188–9.
83. Howard DH.Drug companies' patient-assistance programs–helping patients or profits? N Engl J Med 2014;371:97–9.
84. Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY. The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm 2017;23:407–11.
85. Landwehr MS, Watson SE, Macpherson CF, Novak KA, Johnson RH. The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults. Cancer medicine 2016;5:863–70.
86. American Cancer Society. Programs and resources to help with cancer-related expenses. 2018. Available from: https://www.cancer.org/treatment/finding-and-paying-for-treatment/understanding-health-insurance/ if-you-have-trouble-paying-a-bill/programs-and-resources-to-help-with-cancer-related-expenses.html.
87. Zafar SY, Ubel PA, Tulsky JA, Pollak KI. Cost-related health literacy: a key component of high-quality cancer care. J Oncol Pract 2015;11: 171–3.
88. Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S, et al. Pilot feasibility study of an Oncology Financial Navigation Program. J Oncol Pract 2018;14:e122–e129.
89. Spencer JC, Samuel CA, Rosenstein DL, Reeder-Hayes KE, Manning ML, Sellers JB, et al. Oncology navigators' perceptions of cancer-related financial burden and financial assistance resources. Supp Care Cancer 2018;26:1315–21.
90. Page RD, Newcomer LN, Sprandio JD, McAneny BL. The patient-centered medical home in oncology: from concept to reality. Am Soc Clin Oncol Educ Book 2015:e82–9.
91. Newcomer LN, Malin JL. Payer view of high-quality clinical pathways for cancer. J Oncol Pract 2017;13:148–50.
92. Colligan EM, Ewald E, Ruiz S, Spafford M, Cross-Barnet C, Parashuram S. Innovative oncology care models improve end-of-life quality, reduce utilization and spending. Health Aff 2017;36:433–40.
93. Kohler RE, Goyal RK, Lich KH, Domino ME, Wheeler SB. Association between medical home enrollment and health care utilization and costs among breast cancer patients in a state Medicaid program. Cancer 2015;121:3975–81.
94. Wheeler SB, Kohler RE, Goyal RK, Lich KH, Lin CC, Moore A, et al. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care 2013;51:494–502.
95. Kline RM, Bazell C, Smith E, Schumacher H, Rajkumar R, Conway PH. Centers for Medicare and Medicaid services: using an episode-based payment model to improve oncology care. J Oncol Pract 2015;11: 114–6.
96. Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, et al. The oncology care model: perspectives from the centers for Medicare & Medicaid services and participating oncology practices in academia and the community. Am Soc Clin Oncol Educ Book 2017;37: 460–6.
97. Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by Commercial Health Plans, 2000-2014. JAMA Oncol 2016;2:960–1.